

ALLERGAN

2525 Dupont Drive, P.O. Box 19534, Irvine, California, USA 92623-9534 Telephone: (714) 246-4500 Website: www.allergan.com

Matthew J. Maletta
Corporate Counsel
and Assistant Secretary
Ph: 714/246-5185
Fx: 714/246-4774

August 13, 2002

VIA FEDERAL EXPRESS

Mr. Jonathan G. Katz
Secretary
Securities and Exchange Commission
450 Fifth Street, N.W.
Washington, D.C. 20549

Re: Allergan, Inc. CEO and CFO
Statements Under Oath Pursuant to Section 21(a)(1)
of the Securities and Exchange Act of 1934, as amended

Dear Mr. Katz:


Enclosed on behalf of the Principal Executive Officer and Principal Financial Officer of Allergan, Inc. pursuant to Order 4-460 of the Securities and Exchange Commission (June 27, 2002), please find one (1) original and one (1) copy of each of the following documents:

1. Statement Under Oath of Principal Executive Officer Regarding Facts and Circumstances Relating to Exchange Act Filings; and
2. Statement Under Oath of Principal Financial Officer Regarding Facts and Circumstances Relating to Exchange Act Filings.

Please acknowledge receipt of this letter and the enclosed Statements by file stamping and returning the enclosed copy of this letter and the enclosed copy of each Statement in the self-addressed stamped envelope provided.

Please contact me if you have any questions.

Regards,




Matthew J. Maletta
Corporate Counsel and
Assistant Secretary

Enclosures

Statement Under Oath of Principal Executive Officer Regarding Facts and Circumstances Relating to Exchange Act Filings


I, David E.I. Pyott, Chairman of the Board, President and Chief Executive Officer of Allergan, Inc., state and attest that:

- (1) To the best of my knowledge, based upon a review of the covered reports of Allergan, Inc., and, except as corrected or supplemented in a subsequent covered report:
 - no covered report contained an untrue statement of a material fact as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed); and
 - no covered report omitted to state a material fact necessary to make the statements in the covered report, in light of the circumstances under which they were made, not misleading as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed).
- (2) I have reviewed the contents of this statement with the Company's audit committee.
- (3) In this statement under oath, each of the following, if filed on or before the date of this statement, is a "covered report":
 - Allergan, Inc. Annual Report on Form 10-K filed with the Commission on March 1, 2002;
 - all reports on Form 10-Q, all reports on Form 8-K and all definitive proxy materials of Allergan, Inc. filed with the Commission subsequent to the filing of the Form 10-K identified above; and
 - any amendments to any of the foregoing.




David E. I. Pyott
Chairman of the Board, President and
Chief Executive Officer
(Principal Executive Officer)
August 13, 2002

Subscribed and sworn to
before me this 13th day of
August, 2002.



Notary Public
My Commission Expires: April 19, 2005



Statement Under Oath of Principal Financial Officer Regarding Facts and Circumstances Relating to Exchange Act Filings


I, Eric K. Brandt, Corporate Vice President and Chief Financial Officer of Allergan, Inc., state and attest that:

- (1) To the best of my knowledge, based upon a review of the covered reports of Allergan, Inc., and, except as corrected or supplemented in a subsequent covered report:
 - no covered report contained an untrue statement of a material fact as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed); and
 - no covered report omitted to state a material fact necessary to make the statements in the covered report, in light of the circumstances under which they were made, not misleading as of the end of the period covered by such report (or in the case of a report on Form 8-K or definitive proxy materials, as of the date on which it was filed).
- (2) I have reviewed the contents of this statement with the Company's audit committee.
- (3) In this statement under oath, each of the following, if filed on or before the date of this statement, is a "covered report":
 - Allergan, Inc. Annual Report on Form 10-K filed with the Commission on March 1, 2002;
 - all reports on Form 10-Q, all reports on Form 8-K and all definitive proxy materials of Allergan, Inc. filed with the Commission subsequent to the filing of the Form 10-K identified above; and
 - any amendments to any of the foregoing.



Eric K. Brandt
Corporate Vice President and
Chief Financial Officer
(Principal Financial Officer)
August 13, 2002

Subscribed and sworn to
before me this 13th day of
August, 2002.



Notary Public

My Commission Expires: April 19, 2005

